InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

- Current share price for LTP : $0.475

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$87 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2025 8:51AM $0.500 $0.475 fallen by 5%
$87 Results of Meeting 24 Oct 2025 4:32PM $0.525 $0.475 fallen by 9.52%
$87 AGM Presentation 24 Oct 2025 2:35PM $0.530 $0.475 fallen by 10.38%
$87 LTR increases LevOmega stake to 43% with $1m investment 6 Oct 2025 8:37AM $0.720 $0.475 fallen by 34.03%
$87 Application for quotation of securities - LTP 26 Sep 2025 9:56AM $0.675 $0.475 fallen by 29.63%
$87 Notice of Annual General Meeting/Proxy Form 23 Sep 2025 1:56PM $0.680 $0.475 fallen by 30.15%
$87 LTR Pharma secures 33% ownership in LevOmega Pty Ltd 22 Sep 2025 8:27AM $0.735 $0.475 fallen by 35.37%
$87 FY25 Results Announcement 29 Aug 2025 8:49AM $0.505 $0.475 fallen by 5.94%
$87 Appendix 4G and Corporate Governance Statement 29 Aug 2025 8:49AM $0.505 $0.475 fallen by 5.94%
$87 Appendix 4E and Annual Report to Shareholders 29 Aug 2025 8:48AM $0.505 $0.475 fallen by 5.94%
$87 Appendix 4E and Annual Report to Shareholders 29 Aug 2025 8:48AM $0.505 $0.475 fallen by 5.94%
$87 SPONTAN Case Series - Strong Post-Prostatectomy Results 25 Aug 2025 9:04AM $0.535 $0.475 fallen by 11.21%
$87 18-Month Shelf Life Strengthens SPONTAN Commercialisation 22 Aug 2025 9:23AM $0.360 $0.475 risen by 31.94%
$87 SPONTAN 5x Faster Onset Validated in EU Journal 20 Aug 2025 9:15AM $0.345 $0.475 risen by 37.68%
$87 US ED Specialist Dr Sun Joins LTR Advisory Board 18 Aug 2025 8:41AM $0.355 $0.475 risen by 33.80%
$87 US ED Specialist Dr Pearlman Joins LTR Advisory Board 11 Aug 2025 8:39AM $0.325 $0.475 risen by 46.15%
$87 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2025 8:41AM $0.370 $0.475 risen by 28.38%
$87 Proposed issue of securities - LTP 29 Jul 2025 8:36AM $0.370 $0.475 risen by 28.38%
$87 Notification regarding unquoted securities - LTP 14 Jul 2025 8:40AM $0.285 $0.475 risen by 66.67%
$87 LTP Completes Extractables Study Milestone for SPONTAN 30 Jun 2025 8:32AM $0.300 $0.475 risen by 58.33%
$87 Urological Expert Appointed to LTR Scientific Advisory Board 21 May 2025 8:22AM $0.390 $0.475 risen by 21.79%
$87 SPONTAN Expands Patient Access via National Pharmacy Network 20 May 2025 8:27AM $0.280 $0.475 risen by 69.64%
$87 LTR Signs Collaborative Agreement to Develop OMD Nasal Spray 8 May 2025 8:35AM $0.385 $0.475 risen by 23.38%
$87 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 9:15AM $0.390 $0.475 risen by 21.79%
$87 Change of Registered Office Address 4 Apr 2025 6:05PM $0.365 $0.475 risen by 30.14%

51 - 75 of 152 results

Page 3 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.